NCT06365476 FlexWave Trial: Efficacy of Extracorporeal Shock Wave Therapy in Post-Stroke Upper Limb Spasticity
| NCT ID | NCT06365476 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-04-15 |
| Primary Completion | 2026-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-04-15 with a primary completion date of 2026-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Extracorporeal shock wave therapy (ESWT) has emerged as an effective therapeutic intervention for addressing post-stroke limb spasticity. This research aims to explore the therapeutic implications of focused ESWT for wrist and finger flexor muscles in patients suffering from post-stroke upper limb spasticity.
Eligibility Criteria
Inclusion Criteria: * Individuals aged 18 years or older with unilateral cerebral stroke. * Wrist and finger flexor muscle tone with a score greater than 1 on the Modified Ashworth Scale. * Stable medical condition and vital signs. * Conscious and able to comply with instructions. Exclusion Criteria: * History of more than one stroke, traumatic brain injury, or cerebral neoplasm. * Coexisting central nervous system disorders (e.g., spinal cord injury, Parkinson's disease) or other musculoskeletal diseases affecting muscle tone assessment. * Contraindications for shockwave intervention, such as malignancies, coagulopathies, local infections, or use of cardiac pacemakers. * Undergone shockwave therapy or botulinum toxin injections for post-stroke spasticity in the past three months. * Cognitive, consciousness, or language impairments preventing participation in the intervention or functional assessments.
Contact & Investigator
Shu-mei Yang, MD
PRINCIPAL INVESTIGATOR
National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT06365476 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06365476 currently recruiting?
Yes, NCT06365476 is actively recruiting participants. Contact the research team at b99401109@gmail.com for enrollment information.
Where is the NCT06365476 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06365476 clinical trial?
NCT06365476 is sponsored by National Taiwan University Hospital. The principal investigator is Shu-mei Yang, MD at National Taiwan University Hospital. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.